Literature DB >> 19494109

Regulation of the Src homology 2 domain-containing inositol 5'-phosphatase (SHIP1) by the cyclic AMP-dependent protein kinase.

Jun Zhang1, Scott F Walk, Kodi S Ravichandran, James C Garrison.   

Abstract

Many agents that activate hematopoietic cells use phos pha tidyl ino si tol 3,4,5-trisphosphate (PtdIns 3,4,5-P(3)) to initiate signaling cascades. The SH2 domain-containing inositol 5' phosphatase, SHIP1, regulates hematopoietic cell function by opposing the action of phos pha tidyl ino si tol 3-kinase and reducing the levels of PtdIns 3,4,5-P(3). Activation of the cyclic AMP-de pend ent protein kinase (PKA) also opposes many of the pro-inflammatory responses of hematopoietic cells. We tested to see whether the activity of SHIP1 was regulated via phos pho ryl a tion with PKA. We prepared pure recombinant SHIP1 from HEK-293 cells and found it can be rapidly phos pho ryl a ted by PKA to a stoichiometry of 0.6 mol of PO(4)/mol of SHIP1. In (32)P-labeled HEK-293 cells transfected with SHIP1, stimulation with Sp-adenosine 3',5'-cyclic monophosphorothioate triethylammonium salt hydrate (Sp-cAMPS) or activation of the beta-adrenergic receptor increased the phos pho ryl a tion state of SHIP1. Inhibition of protein phosphatase activity with okadaic acid also increased the phos pho ryl a tion of SHIP1. Phosphorylation of SHIP1 in vitro or in cells by PKA increased the 5' phosphatase activity of SHIP1 by 2-3-fold. Elevation of Ca(2+) in DT40 cells in response to B cell receptor cross-linking, an indicator of PtdIns 3,4,5-P(3) levels, was markedly blunted by pretreatment with Sp-cAMPS. This effect was absent in SHIP(-/-) DT40 cells showing that the effect of Sp-cAMPS in DT40 cells is SHIP1-de pend ent. Sp-cAMPS also blunted the ability of the B cell receptor to increase the phos pho ryl a tion of Akt in DT40 and A20 cells. Overall, activation of G protein-coupled receptors that raise cyclic AMP cause SHIP1 to be phosphorylated and stimulate its inositol phosphatase activity. These results outline a novel mechanism of SHIP1 regulation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19494109      PMCID: PMC2740433          DOI: 10.1074/jbc.M109.016865

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

1.  Essential role for the C-terminal noncatalytic region of SHIP in FcgammaRIIB1-mediated inhibitory signaling.

Authors:  M J Aman; S F Walk; M E March; H P Su; D J Carver; K S Ravichandran
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

2.  Cyclic AMP-dependent inhibition of human neutrophil oxidative activity by substituted 2-propynylcyclohexyl adenosine A(2A) receptor agonists.

Authors:  G W Sullivan; J M Rieger; W M Scheld; T L Macdonald; J Linden
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

3.  p135 src homology 2 domain-containing inositol 5'-phosphatase (SHIPbeta ) isoform can substitute for p145 SHIP in fcgamma RIIB1-mediated inhibitory signaling in B cells.

Authors:  M E March; D M Lucas; M J Aman; K S Ravichandran
Journal:  J Biol Chem       Date:  2000-09-29       Impact factor: 5.157

Review 4.  Review: G-protein-coupled receptors on eosinophils.

Authors:  M A Giembycz; O T Lynch; P M De Souza; M A Lindsay
Journal:  Pulm Pharmacol Ther       Date:  2000       Impact factor: 3.410

Review 5.  Lipid phosphatases in the immune system.

Authors:  G Krystal
Journal:  Semin Immunol       Date:  2000-08       Impact factor: 11.130

6.  The inositol 5-phosphatase SHIP is expressed as 145 and 135 kDa proteins in blood and bone marrow cells in vivo, whereas carboxyl-truncated forms of SHIP are generated by proteolytic cleavage in vitro.

Authors:  S Horn; J Meyer; J Heukeshoven; B Fehse; C Schulze; S Li; J Frey; S Poll; C Stocking; M Jücker
Journal:  Leukemia       Date:  2001-01       Impact factor: 11.528

7.  Enzymatic activity of the Src homology 2 domain-containing inositol phosphatase is regulated by a plasma membrane location.

Authors:  H Phee; A Jacob; K M Coggeshall
Journal:  J Biol Chem       Date:  2000-06-23       Impact factor: 5.157

Review 8.  Adenosine receptors: therapeutic aspects for inflammatory and immune diseases.

Authors:  György Haskó; Joel Linden; Bruce Cronstein; Pál Pacher
Journal:  Nat Rev Drug Discov       Date:  2008-09       Impact factor: 84.694

9.  Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation.

Authors:  E Hirsch; V L Katanaev; C Garlanda; O Azzolino; L Pirola; L Silengo; S Sozzani; A Mantovani; F Altruda; M P Wymann
Journal:  Science       Date:  2000-02-11       Impact factor: 47.728

10.  Differential regulation of B cell development, activation, and death by the src homology 2 domain-containing 5' inositol phosphatase (SHIP).

Authors:  A Brauweiler; I Tamir; J Dal Porto; R J Benschop; C D Helgason; R K Humphries; J H Freed; J C Cambier
Journal:  J Exp Med       Date:  2000-05-01       Impact factor: 14.307

View more
  6 in total

1.  A key role for the phosphorylation of Ser440 by the cyclic AMP-dependent protein kinase in regulating the activity of the Src homology 2 domain-containing Inositol 5'-phosphatase (SHIP1).

Authors:  Jun Zhang; Kodi S Ravichandran; James C Garrison
Journal:  J Biol Chem       Date:  2010-09-01       Impact factor: 5.157

Review 2.  Inhibitor and activator: dual functions for SHIP in immunity and cancer.

Authors:  William G Kerr
Journal:  Ann N Y Acad Sci       Date:  2010-12-13       Impact factor: 5.691

Review 3.  Role of SHIP1 in cancer and mucosal inflammation.

Authors:  Sandra Fernandes; Sonia Iyer; William G Kerr
Journal:  Ann N Y Acad Sci       Date:  2013-03       Impact factor: 5.691

4.  Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.

Authors:  Jeffrey D Cooney; An-Ping Lin; Daifeng Jiang; Long Wang; Avvaru N Suhasini; Jamie Myers; ZhiJun Qiu; Albert Wölfler; Heinz Sill; Ricardo C T Aguiar
Journal:  Clin Cancer Res       Date:  2017-12-15       Impact factor: 12.531

Review 5.  Strategy for Leukemia Treatment Targeting SHP-1,2 and SHIP.

Authors:  Fang Hao; Chen Wang; Christine Sholy; Min Cao; Xunlei Kang
Journal:  Front Cell Dev Biol       Date:  2021-08-19

6.  The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions.

Authors:  Samantha D Pauls; Sandrine T Lafarge; Ivan Landego; Tingting Zhang; Aaron J Marshall
Journal:  Front Immunol       Date:  2012-08-09       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.